Immune-based therapies are transforming advanced liver cancer care, resulting in curative options previously considered unattainable.
In patients with unresectable liver cancer, treatment with Imjudo plus Imfinzi showed better survival outcomes compared with Nexavar. A treatment combination of Imjudo (tremelimumab) and Imfinzi ...
A study presented at Digestive Disease Week 2016 found African American patients diagnosed with hepatocellular carcinoma had a 33 percent increased risk of death compared to non-Hispanic white ...
In November 2025, Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology firm specializing in therapies for primary ...
The industry currently witnesses a paradigm shift toward combination regimens, where oral kinase inhibitors and ...
A report in CA: A Cancer Journal for Clinicians reviewed incidence, mortality and survival rates for liver cancer patients. 1. With an estimated 41,000 new liver cancer cases and around 29,000 liver ...
A new exploratory analysis of the HIMALAYA phase III trial involving patients with unresectable hepatocellular carcinoma (uHCC, an advanced liver cancer that could not be treated with surgery or other ...
The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...
Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback